Q4221 Amniowrap2 HCPCS: Reimbursement & Policy

HCPCS Level II code Q4221 identifies Amniowrap2 billed per square centimeter as an add-on supply in addition to a primary procedure. The code covers a biologic matrix product used intraoperatively or during procedural wound care to support tissue repair. Nationally, add-on supply codes like Q4221 matter because they affect facility and professional billing, itemized supply costs, and the accuracy of claims for advanced wound and surgical adjuncts.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's clinical purpose and service setting, an outline of typical payer considerations, and what to expect in claims processing for add-on biologic supplies. The publication also summarizes common modifiers encountered on related service lines and highlights where data was not provided in the input.

This summary is intended for billing managers, revenue cycle analysts, and clinicians involved in procedural and wound management billing who need a clear, national-level reference for the role and billing context of HCPCS Level II code Q4221.

Billing Code Overview

HCPCS Level II code Q4221 represents Amniowrap2 billed per square centimeter as an add-on, list separately in addition to primary procedure. This itemized supply is used when Amniowrap2 biologic matrix is applied during a procedure and charged in addition to the primary surgical or procedural code.

Service type: Biologic graft or wound care adjunct applied intraoperatively or in procedural wound management
Typical site of service: Hospital outpatient department, ambulatory surgery center, or operating room during a primary procedure

Clinical Context

A patient presents to an outpatient wound care clinic or ambulatory surgical center with a chronic non-healing surgical wound or complex soft-tissue defect over which an amniotic membrane product is indicated to promote healing. Typical patients include adults with diabetic foot ulcers, non-healing venous stasis ulcers, or post-operative wounds with exposed tendon or bone where biologic coverage is used as an adjunct. The clinical workflow: the wound is evaluated, debrided if necessary, and measured. After achieving a clean wound bed, the clinician selects the amniotic membrane product (billed as Q4221 per square centimeter as an add-on), trims and places the graft to cover the defect, secures it with sutures, adhesives, or dressing, and applies an appropriate dressing. The patient receives wound care instructions and scheduled follow-up visits for dressing changes and assessment of graft incorporation and wound healing.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when the work required to apply the amniotic membrane is substantially greater than typical (extensive debridement, complex placement).
`52`

Taxonomy Code	Specialty	Notes
`163W00000X`	Podiatric Medicine & Surgery	Common for diabetic foot and lower-extremity wound applications.
`208000000X`	General Surgery	Applies when general surgeons manage complex soft-tissue defects and place biologic grafts.
`207P00000X`	Obstetrics & Gynecology	OB/GYN providers may use amniotic-derived products for pelvic floor or reconstructive procedures.
`208200000X`	Plastic Surgery	Frequently performs biologic coverage, complex soft-tissue reconstruction, and graft placement.
`364S00000X`	Wound Care & Hyperbaric Medicine	Specialists focused on chronic wound management who commonly apply amniotic membrane products.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E11.621`	Type 2 diabetes mellitus with foot ulcer	Diabetic foot ulcers commonly require biologic adjuncts like amniotic membrane to promote healing.
`L97.322`	Non-pressure chronic ulcer of left lower leg with fat layer exposed	Chronic lower-extremity ulcers often treated with debridement and biologic coverage.
`L97.923`	Non-pressure chronic ulcer of unspecified part of right lower leg with unspecified severity	Represents chronic leg ulcers that may benefit from amniotic membrane application.
`I83.90`	Varicose veins of lower extremities with ulcer, unspecified side	Venous stasis ulcers may require advanced wound therapies including amniotic products.
`S81.811A`	Laceration without foreign body of right knee, initial encounter	Acute surgical wounds with soft-tissue loss where amniotic membrane may be used as an adjunct to promote healing.
`T81.31XA`	Disruption of external operation (wound) of internal prosthetic device, initial encounter	Postoperative wound complications that may be managed with biologic overlay to encourage tissue repair.
`Z48.02`	Encounter for removal of sutures	Relevant to post-procedure follow-up when dressings and sutures are removed after graft placement.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`11042`	Debridement, subcutaneous tissue (e.g., first 20 sq cm)	Surgical debridement prior to application of amniotic membrane to create a healthy wound bed.
`15271`	Application of integumentary allograft to trunk, arms, legs; first 25 sq cm or less	Alternative/related code used for placement of biologic grafts covering soft-tissue defects in similar clinical workflows.
`97602`	Removal of devitalized tissue from wound(s), selective debridement, without anesthesia; without topical instrumentation, per session	Non-surgical selective debridement in clinic before graft application.
`97605`	Negative pressure wound therapy (e.g., initial application)	Adjunctive therapy often used after graft placement to stabilize the graft and manage exudate.
`12002`	Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (simple closure)	Primary wound closure or partial closure performed in conjunction with or prior to biologic placement.

OpenPayer

Summary & Overview

HCPCS Q4221: Amniowrap2, Biologic Matrix Per Sq Cm